Novartis AG ADR (NVS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $303.12B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novartis AG ADR (NVS) P/E Ratio & Valuation History
Novartis AG ADR (NVS) trades at 18.7x trailing earnings and 5.4x sales. Its P/E of 18.7x is above its 5-year median of 14.6x. Its forward P/E is 16.0x. The median P/E across 9 similar companies is 22.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 16.9% higher over the next year. Its free cash flow yield is 4.9%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 18.7x |
| Forward P/E | 16.0x |
| Price to sales | 5.4x |
| Price to book | 8.2x |
| EV/EBITDA | 15.7x |
| Price to FCF | 20.6x |
| EV/FCF | 23.1x |
| PEG | 3.8 |
| FCF yield | 4.9% |
Historical Medians
Against its 10-year medians, its P/E is 22.2% above 15.3x, its P/S is 31.7% above 4.1x and its P/B is 115.8% above 3.8x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 18.7x | 14.6x | 15.3x |
| P/S | 5.4x | 4.4x | 4.1x |
| P/B | 8.2x | 5.0x | 3.8x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 12.5x in 2024 to 17.9x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $137.87 | 15.4x | 4.8x | 5.8x |
| 2024 | $97.31 | 12.5x | 3.8x | 4.4x |
| 2023 | $100.97 | 14.8x | 4.5x | 4.5x |
| 2022 | $90.72 | 14.8x | 4.0x | 3.3x |
| 2021 | $87.47 | 13.9x | 3.7x | 2.9x |
| 2020 | $94.43 | 16.3x | 4.3x | 3.8x |
| 2019 | $94.69 | 17.9x | 4.5x | 3.9x |
| 2018 | $85.81 | 16.7x | 4.2x | 2.5x |
| 2017 | $83.96 | 17.3x | 4.0x | 2.7x |
| 2016 | $72.84 | 15.3x | 3.5x | 2.3x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NVS
What is NVS's forward P/E ratio?
Novartis AG ADR has a forward P/E ratio of 16.0x.
Is NVS stock overvalued?
GNG's valuation label for NVS is Fairly valued. Its P/E of 18.7x compares with a median of 22.5x across 9 similar companies.
What is NVS's price to sales ratio?
Novartis AG ADR has a price to sales ratio of 5.4x.
What is Novartis AG ADR's average P/E ratio over 5 years?
Novartis AG ADR's median P/E over the last 5 years is 14.6x, from 60 month-end values through Oct 2026.
What is NVS's PEG ratio?
Novartis AG ADR has a PEG ratio of 3.8.
NVS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts